Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05203380

Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis — NEURADAD  

Moderate-to-severe Atopic Dermatitis Clinical Trial

Official title:
Neuropsychologic Assessments of Dupilumab-Treated Adolescents With Moderate-to-Severe Atopic Dermatitis

Clinical Trial Summary

Primary Objective: Part A - To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score - To determine the entry criterion (CPT-3 d' score) for Part B Primary Objective: Part B - To measure changes in cognitive functioning in adolescents with moderate-to-severe AD treated with dupilumab Secondary Objectives - To evaluate the relationship of cognitive and sensory functioning with severity of AD in adolescent AD patients - To evaluate the relationship between changes in AD severity and changes in cognitive and sensory functioning scores following treatment with dupilumab (Part B only).

Clinical Trial Description

Per protocol Study Stop Criteria, study has concluded with Part A. Part B was not initiated and no data were collected. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05203380
Study type Observational
Source Regeneron Pharmaceuticals
Contact
Status Completed
Phase
Start date January 27, 2022
Completion date March 10, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT03054428 - Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Phase 3
Active, not recruiting NCT05899816 - A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) Phase 3
Recruiting NCT04893707 - The Study of CM310 in Patients With Atopic Dermatitis Phase 2
Completed NCT03985943 - Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 3
Completed NCT03989349 - Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 3
Recruiting NCT04921345 - Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04893941 - Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD) Phase 1/Phase 2
Completed NCT04444752 - A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Withdrawn NCT05056779 - Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable Phase 3
Recruiting NCT05590585 - Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial Phase 4
Completed NCT04805411 - Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) Phase 2
Recruiting NCT05186922 - The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis Phase 1/Phase 2
Recruiting NCT03057860 - TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis
Active, not recruiting NCT03989206 - Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Phase 3
Recruiting NCT05671432 - The Study of CM326 in Moderate-to-severe Atopic Dermatitis Phase 2
Not yet recruiting NCT06158490 - A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Active, not recruiting NCT05984784 - A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Phase 1/Phase 2
Completed NCT05017480 - A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China Phase 2